CN112807403A - Application of composition in preparation of product for inhibiting prostate cancer - Google Patents

Application of composition in preparation of product for inhibiting prostate cancer Download PDF

Info

Publication number
CN112807403A
CN112807403A CN202011585668.9A CN202011585668A CN112807403A CN 112807403 A CN112807403 A CN 112807403A CN 202011585668 A CN202011585668 A CN 202011585668A CN 112807403 A CN112807403 A CN 112807403A
Authority
CN
China
Prior art keywords
prostate cancer
parts
composition
lycopene
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202011585668.9A
Other languages
Chinese (zh)
Inventor
严建刚
杜玉兰
欧阳道福
喻勤
李晓敏
李翠华
王志芳
古润金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perfect China Co Ltd
Perfect Guangdong Commodity Co Ltd
Original Assignee
Perfect China Co Ltd
Perfect Guangdong Commodity Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perfect China Co Ltd, Perfect Guangdong Commodity Co Ltd filed Critical Perfect China Co Ltd
Priority to CN202011585668.9A priority Critical patent/CN112807403A/en
Publication of CN112807403A publication Critical patent/CN112807403A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention discloses an application of a composition in preparation of a product for inhibiting prostate cancer, wherein the composition comprises the following components in parts by weight: mixing tocopherol, lycopene, turmeric and phytosterol ester. The composition for inhibiting the prostate cancer provided by the invention has the advantages of good efficacy, high safety, no bad taste, no toxic or side effect and suitability for long-term use, and can be applied to common foods.

Description

Application of composition in preparation of product for inhibiting prostate cancer
Technical Field
The invention relates to the technical field of medical food, in particular to application of a composition in preparing a product for inhibiting prostate cancer.
Background
Prostate cancer (Prostate cancer) is the most common malignancy in the male genitourinary system, the second largest malignancy currently second only to skin cancer. The incidence and mortality of prostate cancer tends to increase year by year throughout asia, including china. Sedentary lifestyles, environmental carcinogens, family history of prostate cancer, endogenous factors, and oxidative stress associated with the aging process are all predisposed to inducing prostate cancer. Prostate cancer has become a global health problem as its morbidity, disease burden and mortality have increased.
Researches of Daqing oilfield general hospital pharmacy Maojingli and the like find that curcumin has an anti-tumor effect on prostate cancer tumor-bearing mice and enhances the immune function of the tumor-bearing mice. Guohui research of urology surgery of affiliated Tongji hospital of Tongji medical college of Huazhong university of science and technology shows that curcumin plays a role in inhibiting PC-3 cell proliferation by activating the expression of IkB alpha in PC-3 cells. For LNCaP cells, curcumin may inhibit LNCaP cell proliferation by means of anti-oxidation, inhibition of intracellular metabolite formation, and the like.
The research of a doctor paper on Jiangling, a university of Hebei medical science, finds that the lycopene can obviously inhibit the proliferation of prostate cancer cells in vitro and promote the apoptosis of the prostate cancer cells; lycopene inhibits the development of prostate cancer through anti-inflammatory action, and lycopene also plays a role in immune regulation in prostate cancer; the lycopene effectively inhibits the growth of tumors in vivo and prolongs the survival period of tumor mice. The study of Jiangyang Hospital ginger Yingbo et al, affiliated to the second medical university, shows that vitamin E succinate can inhibit the growth and proliferation of prostate cancer P C-3 cells and induce the apoptosis of the prostate cancer P C-3 cells. The research of K.F.KLIPPEL and the like of the university of Dreuston theory and worker finds that the beta-sitosterol has the effect of improving the prostatic hyperplasia.
However, no relevant documents or published technologies are deeply researched, whether the combination of multiple components has a synergistic effect is researched, no relevant published technologies or technical suggestions show that the turmeric, the phytosterol, the mixed tocopherol and the lycopene can be combined to jointly inhibit the effect of the prostate cancer, and the application of the four substances in the preparation of products for inhibiting the prostate cancer does not appear in the prior art.
Disclosure of Invention
Based on the above, the present invention aims to overcome the defects of the prior art and provide the application of a composition in the preparation of a product for inhibiting prostate cancer.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows: use of a composition in the manufacture of a product for inhibiting prostate cancer, the composition comprising the following components: mixing tocopherol, lycopene, turmeric and phytosterol ester.
Preferably, the article of manufacture comprises a food, pharmaceutical or nutraceutical product.
According to the invention, the turmeric, the lycopene, the mixed tocopherol and the phytosterol ester are compounded, and the test data shows that the raw materials have a synergistic interaction effect for the first time, so that the prostate cancer can be effectively inhibited, and the use effect is better than that of the single use, the combination of the turmeric and the lycopene and the combination of the mixed tocopherol and the lycopene.
In addition, the composition provided by the invention has high safety and no toxic or side effect, and the turmeric is a medicine and food dual-purpose raw material abroad, is particularly widely applied to india and is a main raw material of curry powder. Turmeric is a food additive and a health food raw material in China, and is widely used in foods. The mixed tocopherol is an antioxidant and a nutrition enhancer, tests prove that 5000 cases of the mixed tocopherol has no adverse reaction after 1000IU is ingested every day for 11 years, the lycopene is a health food raw material and a food pigment, and Sun Jie tests of the public health academy of Nanjing medical university prove that the lycopene is safe and non-toxic. The phytosterol ester is a new food raw material and can be applied to common foods, so that the composition has high safety.
Meanwhile, the components in the composition can be prepared and extracted according to actual conditions, can be directly purchased from the market, and can be replaced by raw materials, semi-finished products or added finished products with the same components without influencing the efficacy of the prepared product: the Curcuma rhizome can be replaced by Curcuma rhizome product, such as curcumin; the mixed tocopherol can be replaced by one or a mixture of several tocopherols of different molecular formulas or compounds with similar structures; the phytosterol ester can be one or more of sitosterol, campesterol, cholesterol, stigmasterol, Δ 7-avenasterol, etc.; lycopene can be a lycopene-rich material extracted from plants or can be biologically fermented or chemically synthesized to contain lycopene or structural analogs.
Preferably, the composition comprises the following components in parts by weight: 12.5-25 parts of mixed tocopherol, 12.5-25 parts of lycopene, 12.5-25 parts of turmeric and 50-100 parts of phytosterol ester.
According to the invention, turmeric, lycopene, mixed tocopherol and phytosterol ester are compounded, and test data shows that materials can generate a synergistic interaction effect, so that prostate cancer can be effectively inhibited. The composition is prepared by compounding turmeric, lycopene, mixed tocopherol and phytosterol ester, and the lycopene can reduce oxidative DNA damage in prostate tissues of prostate cancer patients. Can enhance the gap junction communication of in vitro tumor cells and inhibit the transformation of normal cells to tumor cells; the mixed tocopherol concentrate has a strong inhibiting effect on the growth of prostate cancer LNCaP tumor, and can also have a strong inhibiting effect on the formation of tumor; curcuma rhizome has effects of inhibiting prostate cancer cell proliferation, inhibiting 15-lipoxygenase (15-LOX), and inducing apoptosis of hormone-dependent prostate cancer cell LNCaP and hormone-independent prostate cancer cell PC-3. The composition can improve the prostate cancer from multiple sites and multiple ways, and the composition can have synergistic effect, so that the prostate health can be better improved.
Preferably, the article further comprises adjuvants including flavoring agents, thickening agents, disintegrating agents, and fillers. On the premise of not influencing the main components of the prostate cancer inhibition product, the necessary auxiliary materials are added in the product to further enhance and provide the taste, the storage stability, the medicinal effect and the like of the product, and the person skilled in the art can select the common content according to the conventional standard.
In addition, the invention also provides a preparation method of the product, which comprises the following steps: and uniformly mixing the composition and the auxiliary materials to obtain the product. The preparation form of the product can be adjusted according to the actual requirement on the premise of not influencing the component structure and the component stability of the composition.
Preferably, the dosage form of the prostate cancer inhibition product comprises solid beverage, granules, capsules and tablets.
Compared with the prior art, the invention has the beneficial effects that: (1) the product has good efficacy, the effect of the invention is better than that of the invention when the product is used alone, and the effect of the invention when the turmeric and the lycopene or the mixed tocopherol and the lycopene are used in a compound way to treat the prostatic cancer. (2) The food additive is high in safety and suitable for long-term use, and the used raw materials of the food additive are food raw materials (new food raw materials) or food additives, can be applied to common food, have no toxic or side effect, and are suitable for long-term use. (3) Has no bad taste, no bitter and astringent taste of the raw materials, no influence on the taste of the product when used alone or added into food, and no difficulty in swallowing like traditional Chinese medicines.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
Example 1
In one embodiment of the present application, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 25 parts of mixed tocopherol, 12.5 parts of lycopene, 12.5 parts of turmeric and 100 parts of phytosterol ester.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: and uniformly mixing the mixed tocopherol, the lycopene, the turmeric and the phytosterol ester to obtain the composition.
Example 2
In one embodiment of the present application, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 12.5 parts of mixed tocopherol, 25 parts of lycopene, 25 parts of turmeric and 100 parts of phytosterol ester.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: and uniformly mixing the mixed tocopherol, the lycopene, the turmeric and the phytosterol ester to obtain the composition.
Example 3
In one embodiment of the present application, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 25 parts of mixed tocopherol, 25 parts of lycopene, 12.5 parts of turmeric and 100 parts of phytosterol ester.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: and uniformly mixing the mixed tocopherol, the lycopene, the turmeric and the phytosterol ester to obtain the composition.
Example 4
In one embodiment of the present application, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 25 parts of mixed tocopherol, 25 parts of lycopene, 25 parts of turmeric and 100 parts of phytosterol ester.
The preparation method of the composition for inhibiting prostate cancer described in the examples is: and uniformly mixing the mixed tocopherol, the lycopene, the turmeric and the phytosterol ester to obtain the composition.
Example 5
In one embodiment of the present application, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 25 parts of mixed tocopherol, 25 parts of lycopene, 25 parts of turmeric and 100 parts of phytosterol ester. The composition is used for preparing a product for inhibiting prostate cancer, and the product also comprises auxiliary materials, wherein the auxiliary materials comprise the following components in parts by weight: 30 parts of flavoring agent, 50 parts of microcrystalline cellulose, 40 parts of maltodextrin, 305 parts of povidone K, 2 parts of silicon dioxide and 3 parts of magnesium stearate.
The preparation method of the prostate cancer inhibiting preparation comprises the following steps: sieving and weighing the raw materials respectively according to the parts by weight, feeding the raw materials into a mixer, uniformly mixing, granulating, tabletting and bottling to prepare tablets, thus obtaining the product.
Example 6
In one embodiment of the present application, the composition for inhibiting prostate cancer comprises the following components in parts by weight: 12.5 parts of mixed tocopherol, 12.5 parts of lycopene, 25 parts of turmeric and 50 parts of phytosterol ester. The composition is used for preparing a product for inhibiting prostate cancer, and the product also comprises auxiliary materials, wherein the auxiliary materials comprise the following components in parts by weight: 4 parts of beeswax, 100 parts of gelatin, 50 parts of glycerol and 100 parts of purified water.
The preparation method of the prostate cancer inhibiting preparation comprises the following steps: mixing, homogenizing, melting gelatin, pressing, washing, drying, selecting pill, and packaging to obtain soft capsule.
Meanwhile, the present application provides comparative examples, and the specific comparison examples are shown in table 1 below, and the preparation method of the composition for inhibiting prostate cancer according to the comparative examples is the same as that of example 1:
table 1 selection of Components and parts by weight of the specific comparative examples
Mixed tocopherols Lycopene Turmeric root tuber Phytosterol esters
Comparative example 1 100
Comparative example 2 50
Comparative example 3 25 12.5 12.5
Comparative example 4 12.5 25 25
Test examples
First, main material and equipment
1.1. Prostate cancer LNCaP cells;
1.2. dimethyl sulfoxide (DM SO), trypan blue, 1640 culture solution, fetal calf serum and trypsin
1.3. Positive control for effect on prostate cancer LNCaP cells: docetaxel, sample component raw materials: turmeric is supplied by Ar juna Natural Extracts Ltd, and phytosterol esters, lycopene, mixed tocopherols are supplied by basf.
1.435 mm petri dish, carbon dioxide incubator, Cytospin centrifuge, microscope (Nikon Optiphot).
Second, test method
2.1 test group
TABLE 2 test groups
Figure BDA0002865385810000061
Figure BDA0002865385810000071
2.2 test methods
Effect on prostate cancer LNCaP cells
Prostate cancer cells were seeded at a concentration of 0.2X 105The cells/mL were plated in 35mm diameter dishes at 5% CO2 and incubated overnight at 37 ℃. Groups of test samples dissolved in DMSO were added and 72 hours later, the effect of different concentrations of each sample on cell growth and death was determined using trypan blue staining. The specific method comprises the following steps: digesting the adherent cells by pancreatin, uniformly mixing 80 μ L of the cell suspension with 20 μ L of 0.4% trypan blue, standing for 2 min, and allowingObserved and counted with a microscope (Nikon Optiphot), and under the visual field, bright transparent cells are counted as live cells, and trypan blue cells are counted as dead cells.
The percentage of viable cells is the number of component viable cells ÷ the number of blank viable cells × 100%
Percent inhibition is (number of blank control living cells-number of component living cells)/number of blank control living cells × 100%
2.3 test results
Effect on prostate cancer LNCaP cells
TABLE 3 Effect of groups on prostate cancer LNCaP cells
Group of Number of viable cells 104 Living cells%
Blank group 14.66±0.45 100
Docetaxel 8.01±0.41 54.63###
Phytosterol 1 11.57±0.16 78.96##
Phytosterol group 2 11.87±0.42 80.99##
Mixed tocopherol + lycopene + turmeric group 1 10.66±0.211 72.72##
Mixed tocopherol + lycopene + turmeric group 2 7.66±0.14 52.24###
Test group 1 9.34±0.27 63.75##*&
Test group 2 5.99±0.27 40.90###***&&
Note that 1.# is relative to the blank control group, & is relative to the same concentration phytosterol ester group, & is relative to the same concentration mixed tocopherol + lycopene + turmeric group; 2. three identical symbols indicate p <0.001, two identical symbols indicate p <0.01, and are extremely significant, and one identical symbol indicates p <0.05, and significantly, the smaller the p value, the more significant the difference.
The table shows that the positive control group has very significant difference from the blank group, and the test group, the phytosterol ester group and the mixed tocopherol + lycopene + turmeric group have very significant difference from the blank group, which indicates that the groups have obvious inhibition effect on prostate cancer LNCaP cells.
The test group 1 has obvious inhibition and apoptosis effects on prostate cancer LNCaP cells, the living cell rate is 63.75%, the inhibition rate on the LNCaP cells is 36.25%, and compared with the plant sterol ester group, the mixed tocopherol + lycopene + turmeric group with the same concentration, the living cell rate is obviously different.
The test group 2 has obvious inhibition and apoptosis effects on prostate cancer LNCaP cells, the living cell rate is 40.90%, the inhibition rate on the LNCaP cells is 59.10%, the effect is better than that of a positive control sample, and the living cell rates of the plant sterol ester group and the mixed tocopherol + lycopene + turmeric group under the same concentration are very obviously different.
Therefore, the turmeric, lycopene, mixed tocopherol and phytosterol ester compound have a synergistic effect on the apoptosis of the prostate cancer LNCaP cells.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

Claims (5)

1. Use of a composition in the manufacture of a product for inhibiting prostate cancer, the composition comprising the following components: mixing tocopherol, lycopene, turmeric and phytosterol ester.
2. The use according to claim 1, wherein the composition comprises the following components in parts by weight: 12.5-25 parts of mixed tocopherol, 12.5-25 parts of lycopene, 12.5-25 parts of turmeric and 50-100 parts of phytosterol ester.
3. The use of claim 1 or 2, wherein the article further comprises adjuvants including flavoring agents, thickening agents, disintegrating agents, and bulking agents.
4. The use of claim 3, wherein the article is prepared by a method comprising: and uniformly mixing the composition and the auxiliary materials to obtain the product.
5. The use of claim 3, wherein the prostate cancer inhibitor is in the form of solid beverage, granule, capsule, or tablet.
CN202011585668.9A 2020-12-28 2020-12-28 Application of composition in preparation of product for inhibiting prostate cancer Withdrawn CN112807403A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011585668.9A CN112807403A (en) 2020-12-28 2020-12-28 Application of composition in preparation of product for inhibiting prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011585668.9A CN112807403A (en) 2020-12-28 2020-12-28 Application of composition in preparation of product for inhibiting prostate cancer

Publications (1)

Publication Number Publication Date
CN112807403A true CN112807403A (en) 2021-05-18

Family

ID=75854931

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011585668.9A Withdrawn CN112807403A (en) 2020-12-28 2020-12-28 Application of composition in preparation of product for inhibiting prostate cancer

Country Status (1)

Country Link
CN (1) CN112807403A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619329A (en) * 2011-04-07 2014-03-05 利库德有限公司 Synergistic compositions and methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619329A (en) * 2011-04-07 2014-03-05 利库德有限公司 Synergistic compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
唐莉莉: "番茄红素对前列腺癌的作用及其机制研究", 《豆丁网》 *

Similar Documents

Publication Publication Date Title
KR101073985B1 (en) Anticancer Composition Comprising Plant Stem Cell Line Derived from Taxus Cambium or Procambium, Lysate, Extract or Media Thereof
ES2672871T3 (en) Fermentation product of the embryonic soy axis containing equol and method of obtaining it
US9950021B2 (en) Anti-cancer active substance from Antrodia camphorata, method for preparing the same and use thereof
JP5667561B2 (en) Neurite outgrowth agent, memory improving agent, anti-Alzheimer agent containing 4&#39;-demethylnobiletin or 4&#39;-demethyltangeretin as an active ingredient, and method for producing the same
JPH0249091A (en) Astaxanthin-containing composition
JP2013155192A (en) Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof
CN108451979B (en) Lycopene compound preparation with auxiliary treatment effect on prostate cancer and application thereof
KR101806808B1 (en) Composition for preventing, improving or treating female menopausal syndrome comprising Pleuropterus multiflorus fermented using Lentinus edodes mycelium as effective component
Song et al. Effects of dietary ginsenoside rg1 supplementation on growth performance, gut health, and serum immunity in broiler chickens
Shen et al. Effect of echinacea purpurea extract given in drinking water on performance, slaughter variables, and meat quality of broilers
CN112807403A (en) Application of composition in preparation of product for inhibiting prostate cancer
CN101948453B (en) Novel NEO-clerodane typed diterpene compound and application thereof
CN112603982A (en) Composition for inhibiting prostatic hyperplasia
CN112790381A (en) Application of composition in preparation of product for inhibiting prostate cancer
CN113577220A (en) Medicinal composition for inhibiting prostate cancer and application thereof
TW201420608A (en) Anticancer and anti-obesity cyclic peptide agents
CN112674340A (en) Application of composition in preparation of product for inhibiting prostate cancer
KR20220169108A (en) Method for producing gold nanoparticle using strain from ginseng and nigella sativa extract and pharmaceutical composition for treating cancer comprising the gold nanoparticle
CN105503800A (en) Novel eremophilanolides type compound and preparation method and medical application thereof
CN112656914A (en) Application of composition in preparation of product for inhibiting prostate cancer
Yu et al. Effects of curcumin and soy isoflavones on genomic instability of human colon cells NCM460 and SW620
CN113144134A (en) Pharmaceutical composition for inhibiting prostate cancer and application thereof
JP2016079163A (en) Composition for treating tumor, and production method thereof
CN112656915A (en) Composition for inhibiting prostatic hyperplasia
JP7289884B2 (en) Anticancer drug composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20210518

WW01 Invention patent application withdrawn after publication